Revelation Biosciences Presents Additional Data Analysis From PRIME Study At International Conference On AKI & CRRT 2026

Revelation Biosciences, Inc. (NASDAQ: REVB) presented additional positive data from the PRIME Study at the International Conference on AKI & CRRT 2026, highlighting the efficacy of their proprietary formulation, Gemini, in normalizing cellular inflammation and restoring immunocompetence in chronic kidney disease (CKD) patients. The study showed that over 85% of patients had elevated cytokines before treatment, with Gemini significantly reducing these levels post-dose (p<0.01 to p<0.03) and improving responsiveness to stimulation. The data suggests that a single dose of Gemini can durably address inflammation and immunoparalysis in CKD patients.